search
Back to results

A Single-Blind Placebo Run-In Study of Venlafaxine for Activity-Limiting Osteoarthritis Pain

Primary Purpose

Osteoarthritis, Pain

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Venlafaxine
Sponsored by
University of Washington
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis focused on measuring osteoarthritis pain, activity limitation, antidepressant, depression, single-blind

Eligibility Criteria

50 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 50 - 80 years
  • Physician diagnosis of OA in hip, knee or spine
  • Significant activity limitation due to pain for at least one month on the Western Ontario and McMasters University Osteoarthritis Index (WOMAC) and average pain more than 5/10 on Brief Pain Inventory despite adequate treatment with acetaminophen or NSAIDs (This will identify an OA group with significant psychological distress and a desire for treatment).
  • Depression status is not restricted, but will be monitored with PRIME-MD interview and the SCL-20. We anticipate depressive symptoms will be common in this population due to the above requirement for activity limitation.

Exclusion Criteria:

  • Cannot read and write English
  • Significant cognitive impairment
  • History of psychosis or mania
  • Current suicidal ideation
  • Current substance abuse or dependence
  • Current use of opioids or any antidepressant medication
  • Use of investigational drug within the past month

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    A

    Arm Description

    All subjects receive placebo for the first two weeks and then Venlafaxine for the next 10 weeks, but they are blind to what they are receiving

    Outcomes

    Primary Outcome Measures

    Difference in average pain intensity on Brief Pain Inventory
    Difference in pain intensity on Western Ontario McMasters University Osteoarthritis Index (WOMAC)

    Secondary Outcome Measures

    Difference in pain interference on Western Ontario McMasters University Osteoarthritis Index (WOMAC)
    Difference in role function as assessed by the Sheehan Disability Scale
    Difference in observed physical function as assessed by the Aggravated Locomotor Function Score

    Full Information

    First Posted
    January 25, 2008
    Last Updated
    January 25, 2008
    Sponsor
    University of Washington
    Collaborators
    Wyeth is now a wholly owned subsidiary of Pfizer
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00611676
    Brief Title
    A Single-Blind Placebo Run-In Study of Venlafaxine for Activity-Limiting Osteoarthritis Pain
    Official Title
    A Single-Blind Placebo Run-In Study of Venlafaxine for Activity-Limiting Osteoarthritis Pain
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2008
    Overall Recruitment Status
    Completed
    Study Start Date
    September 2004 (undefined)
    Primary Completion Date
    February 2007 (Actual)
    Study Completion Date
    February 2007 (Actual)

    3. Sponsor/Collaborators

    Name of the Sponsor
    University of Washington
    Collaborators
    Wyeth is now a wholly owned subsidiary of Pfizer

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This will be a single-blind, placebo-run-in trial. Subjects will be informed that they may receive Venlafaxine or placebo during the course of the trial. All subjects will, in fact, receive placebo for the first two weeks. All subjects will then be placed on 150-225 mg per day of venlafaxine. Primary outcome assessment will compare pain intensity at 2 weeks (after placebo) to that at 12 weeks (after 10 weeks of Venlafaxine treatment). Study Hypothesis: In subjects who continue to have activity-limiting osteoarthritis pain after treatment with acetaminophen or non-steroidal anti-inflammatory agents, 150-225 mg Venlafaxine per day over 10 weeks will provide significant additional pain relief over that achieved with placebo (more than 30% reduction after Venlafaxine treatment).

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Osteoarthritis, Pain
    Keywords
    osteoarthritis pain, activity limitation, antidepressant, depression, single-blind

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Single Group Assignment
    Masking
    Participant
    Allocation
    Non-Randomized
    Enrollment
    18 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    A
    Arm Type
    Experimental
    Arm Description
    All subjects receive placebo for the first two weeks and then Venlafaxine for the next 10 weeks, but they are blind to what they are receiving
    Intervention Type
    Drug
    Intervention Name(s)
    Venlafaxine
    Intervention Description
    Weeks 0-2: placebo. Weeks 2-3: 75 mg Venlafaxine. Weeks 3-4: 150 mg Venlafaxine. Weeks 4-12: 150-225 mg Venlafaxine.
    Primary Outcome Measure Information:
    Title
    Difference in average pain intensity on Brief Pain Inventory
    Time Frame
    Between 2 weeks and 12 weeks
    Title
    Difference in pain intensity on Western Ontario McMasters University Osteoarthritis Index (WOMAC)
    Time Frame
    Between 2 weeks and 12 weeks
    Secondary Outcome Measure Information:
    Title
    Difference in pain interference on Western Ontario McMasters University Osteoarthritis Index (WOMAC)
    Time Frame
    Between 2 and 12 weeks
    Title
    Difference in role function as assessed by the Sheehan Disability Scale
    Time Frame
    Between 2 and 12 weeks
    Title
    Difference in observed physical function as assessed by the Aggravated Locomotor Function Score
    Time Frame
    Between 2 and 12 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    50 Years
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Age 50 - 80 years Physician diagnosis of OA in hip, knee or spine Significant activity limitation due to pain for at least one month on the Western Ontario and McMasters University Osteoarthritis Index (WOMAC) and average pain more than 5/10 on Brief Pain Inventory despite adequate treatment with acetaminophen or NSAIDs (This will identify an OA group with significant psychological distress and a desire for treatment). Depression status is not restricted, but will be monitored with PRIME-MD interview and the SCL-20. We anticipate depressive symptoms will be common in this population due to the above requirement for activity limitation. Exclusion Criteria: Cannot read and write English Significant cognitive impairment History of psychosis or mania Current suicidal ideation Current substance abuse or dependence Current use of opioids or any antidepressant medication Use of investigational drug within the past month
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Mark D. Sullivan, MD, PhD
    Organizational Affiliation
    University of Washington
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    A Single-Blind Placebo Run-In Study of Venlafaxine for Activity-Limiting Osteoarthritis Pain

    We'll reach out to this number within 24 hrs